EAACI Congress 2023
BackBiologicals in asthma – from clinical trials to real life
Friday 09 Jun, 16:45 PM -
18:15 PM CEST
Hall Y 05+06
ORAL Session
16:45
Dupilumab Treatment Induces Clinical Remission in Patients with Uncontrolled, Moderate-to-Severe, Type 2 Inflammatory Asthma
16:57
Targeting type 2 inflammation: Use of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps and the effect on co-existing asthma. The experience of the Allergy Unit ‘’D. Kalogeromitros’ in Greece
17:09
Unraveling new biomarkers for asthma treatment monitoring with biologics using metabolomics
17:21
ORBE II: Analysis of atopic vs non-atopic patients with severe asthma treated with benralizumab in clinical practice in Spain
17:33
ILC2, MSF, PTX3 AND GAL3 regulation in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps treated with mepolizumab: study protocol
17:45
Lung function in asthmatic old patient under antibody monoclonal therapy: the experience from a Portuguese tertiary hospital
17:57
ORBE II Study: Analysis of benralizumab-treated patients according to baseline FeNO